Comprehensive Safety Exposure-Response Analysis to Support Ritlecitinib Dose Selection

The study on ritlecitinib, a kinase inhibitor for treating alopecia areata, focused on its safety profile through comprehensive exposure-response analyses. The research, based on a Phase 2b/3 study, found no evidence of QTc prolongation and only a marginal decrease in lymphocytes, with a small predicted incidence of Grade 3/4 lymphopenia, except for a slight increase with a loading dose. The incidence of infections and rash increased with dose but was not proportionally large. Safety was consistent across patient subgroups, including adolescents, with no unique risks identified. These findings supported the selection of a 50 mg non-loading dose regimen for both adults and adolescents.